Areteia

Pioneering a New Era In Asthma Control

Our Advanced Candidate: Dexpramipexole

Who We Are

About Us
Eosinophilic Asthma

A New Approach

How Did We Get Here?

Phase 3 Development Program

News Releases

Publications

Presentations

Contact
Home Pioneering a New Era
In Asthma Control
Our Advanced Candidate: Dexpramipexole Who We Are
About Us Eosinophilic Asthma
Our Science A New Approach How Did We Get Here Phase 3 Development Program
News News Releases Publications Presentations
Contact

News

  • News Releases
  • Publications
  • Presentations

2023

01.10.23

Areteia Therapeutics company presentation
JP Morgan Healthcare Conference

Read More

2022

02.28.22

Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 demonstrating that oral dexpramipexole improves airflow obstruction as measured by forced expiry volume (FEV1), largely through its effect on forced vital capacity (FVC)

Read More

2021

09.07.21

Phase 2 Trial Evaluating the Effect of Dexpramipexole on Eosinophil Biomarkers and Lung Function in Asthma

Read More

05.14.21

Oral Dexpramipexole Efficacy in Lowering Blood Eosinophils in Patients with Moderate to Severe Uncontrolled Eosinophilic Asthma

Read More

2019

07.09.19

Dexpramipexole Responsiveness is Increased in Eosinophilic Subjects

Read More

07.09.19

Developing Dexpramipexole for the Treatment of Eosinophilic Disorders

Read More

Areteia
Home
|
About Us
|
Eosinophilic Asthma
|
Our Science
|
News
|
Contact
Terms of Service
Accessibility Policy
Privacy
Recruitment Fraud Alert

© 2023 Areteia Therapeutics